- Home
- CCCC vs GBLI Comparison
CCCC vs GBLI Comparison
Compare CCCC & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCCC | GBLI |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.6M | 358.1M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CCCC | GBLI |
|---|---|---|
| Price | $3.22 | $24.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $12.63 | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 4.5K |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 5.72% |
| EPS Growth | ★ 16.45 | N/A |
| EPS | N/A | ★ 1.05 |
| Revenue | $35,947,000.00 | ★ $450,098,000.00 |
| Revenue This Year | N/A | $6.60 |
| Revenue Next Year | N/A | $13.62 |
| P/E Ratio | ★ N/A | $23.31 |
| Revenue Growth | 1.02 | ★ 2.02 |
| 52 Week Low | $1.69 | $22.83 |
| 52 Week High | $5.17 | $30.50 |
Technical Indicators
Market Signals| Indicator | CCCC | GBLI |
|---|---|---|
| Relative Strength Index (RSI) | 51.52 | 43.39 |
| Support Level | $2.55 | $22.83 |
| Resistance Level | $3.25 | $28.94 |
| Average True Range (ATR) | 0.20 | 0.67 |
| MACD | 0.06 | 0.17 |
| Stochastic Oscillator | 65.43 | 34.98 |
Price Performance
Historical ComparisonAbout CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.